SRPT Stock Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$83.19|
|52 Week High||US$181.83|
|52 Week Low||US$65.30|
|1 Month Change||2.04%|
|3 Month Change||3.33%|
|1 Year Change||-45.74%|
|3 Year Change||-33.76%|
|5 Year Change||141.20%|
|Change since IPO||113.31%|
Recent News & Updates
Sarepta: Revenue Keeps Rising While We Wait For Functional Data
SRPT has continued growing its revenue line despite not producing placebo compared data. The stock dropped hugely in January after a trial failure and hasn't recovered since. Some have asked if they even need to produce placebo-controlled trial data.
Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|SRPT||US Biotechs||US Market|
Return vs Industry: SRPT underperformed the US Biotechs industry which returned 2% over the past year.
Return vs Market: SRPT underperformed the US Market which returned 17.8% over the past year.
|SRPT Average Weekly Movement||6.5%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||14.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: SRPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SRPT's weekly volatility (7%) has been stable over the past year.
About the Company
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Sarepta Therapeutics Fundamentals Summary
|SRPT fundamental statistics|
Is SRPT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SRPT income statement (TTM)|
|Cost of Revenue||US$868.73m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-5.58|
|Net Profit Margin||-75.30%|
How did SRPT perform over the long term?See historical performance and comparison
Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: SRPT ($83.19) is trading above our estimate of fair value ($79.25)
Significantly Below Fair Value: SRPT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SRPT is overvalued based on its PB Ratio (15.4x) compared to the US Biotechs industry average (2.7x).
How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: SRPT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SRPT's is expected to become profitable in the next 3 years.
Revenue vs Market: SRPT's revenue (27.7% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: SRPT's revenue (27.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRPT is forecast to be unprofitable in 3 years.
How has Sarepta Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRPT is currently unprofitable.
Growing Profit Margin: SRPT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of 30% per year.
Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: SRPT has a negative Return on Equity (-103.53%), as it is currently unprofitable.
How is Sarepta Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SRPT's short term assets ($2.2B) exceed its short term liabilities ($373.4M).
Long Term Liabilities: SRPT's short term assets ($2.2B) exceed its long term liabilities ($1.8B).
Debt to Equity History and Analysis
Debt Level: SRPT has more cash than its total debt.
Reducing Debt: SRPT's debt to equity ratio has increased from 4.6% to 233.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SRPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SRPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Ingram (58 yo)
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as Director of Relay Therapeutics,...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD1.29M) is below average for companies of similar size in the US market ($USD6.26M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
Experienced Management: SRPT's management team is considered experienced (2.1 years average tenure).
Experienced Board: SRPT's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SRPT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.
Sarepta Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Sarepta Therapeutics, Inc.
- Ticker: SRPT
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.157b
- Shares outstanding: 87.08m
- Website: https://www.sarepta.com
Number of Employees
- Sarepta Therapeutics, Inc.
- 215 First Street
- Suite 415
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 23:33|
|End of Day Share Price||2021/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.